cas：169590-41-4 Deracoxib;SC 046; SC 46; SC 59046 原料药研发

产品名称：cas：169590-41-4 Deracoxib;SC 046; SC 46; SC 59046 原料药研发

产品描述：

Product Name：Deracoxib

Synonyms：SC 046; SC 46; SC 59046

CAS Number：169590-41-4

M. Wt：397.37

Target：Apoptosis; COX

Pathway：Apoptosis; Immunology/Inflammation
Approved Type:Other Countries

Biological Activity：Deracoxib, a selective cyclooxygenase-2 inhibitor, is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID).
IC50 Value: 70 to 150 uM(inhibition of 3 osteosarcoma cell lines) [1]

Target: COX
in vitro: Concentration of deracoxib required for 50% inhibition of cell viability (IC50) was reached in all 3 osteosarcoma cell lines and ranged from 70 to 150 microM, whereas the IC50 for piroxicam was only reached in the POS cell line at 500 microM. Neither deracoxib nor piroxicam induced sufficient toxicity in fibroblasts to reach an IC50. Exposure of osteosarcoma cells to cytotoxic concentrations of deracoxib and piroxicam did not result in DNA fragmentation [1]. Concomitant treatment of cells with piroxicam and deracoxib resulted in significant induction of apoptosis at lower concentrations and accumulation of cells in the G /G phase. Significant cytotoxic effects exhibited by the combination of piroxicam and deracoxib against canine mammary carcinoma cells in vitro suggest an attractive approach for the treatment of canine mammary carcinoma [2].
in vivo: Perioperative administration of deracoxib to dogs at 1-2 mg/kg/day for 3 days significantly improves analgesia in the postoperative surgical period after soft tissue surgery [3]. Dogs were treated PO with deracoxib at a dosage of 3 mg/kg/d (1.36 mg/lb/d) as a single-agent treatment for TCC. Tumor response was assessed via radiography, abdominal ultrasonography, and ultrasonographic mapping of urinary bladder masses. Toxic effects of deracoxib administration in dogs were assessed through clinical observations and hematologic and biochemical analyses. 24 dogs for which tumor response was assessed, 4 (17%) had partial remission, 17 (71%) had stable disease, and 3 (13%) had progressive disease; initial response could not be assessed in 2 of 26 dogs. The median survival time was 323 days. Median time to progressive disease was 133 days. Renal, hepatic, and gastrointestinal abnormalities attributed to deracoxib administration were noted in 4% (1/26), 4% (1/26), and 19% (5/26) of dogs, respectively [4].

规格：50mg，100mg，500mg，1g，10g，100g以及kg级别等公斤级大包装

配送：惯例下常温包邮

包装：袋装

厂家：西安齐岳生物科技有限公司

关于我们：
西安齐岳生物科技有限公司具备批量生产能力和强大的研发能力，这样的双重优势可以确保企业不仅在满足市场需求上保持高效，同时也在产品创新和技术升级。能够提供100mg，500mg，1g，10g，100g以及kg级别等公斤级大包装。

运输说明:
极低温产品:极低温产品运输过程中加装干冰运输。

低温产品:低温产品运输过程中加装冰袋运输。

常温产品:常温产品运输过程中无需加冰或者特殊包装

温馨提示：西安齐岳生物提供的产品仅用于科研！

随货带检测图谱，提供各种规格包装的价格以及技术资料

温馨提示：仅用于科研

联系我们：

邮箱：2519696869@qq.com

QQ: 2519696869

电话：18066853083

微信：18066853083

公司介绍：

西安齐岳生物科技有限公司是集化学科研和定制与一体的高科技化学公司。业务范围包括化学试剂和产品的研发、生产、销售等。涉及产品为通用试剂的分销、非通用试剂的定制与研发，涵盖生物科技、化学品、中间体和化工材料等领域。
主营产品：COF、MOF单体系列：三蝶烯衍生物、金刚烷衍生物、四苯甲烷衍生物、peg、上转换、石墨烯、光电材料、点击化学、凝集素、载玻片、蛋白质交联剂、脂质体、蛋白、多肽、氨基酸、糖化学等。